Morgan Stanley Reiterates Overweight Rating on Rhythm Pharmaceuticals (RYTM)
Tweet Send to a Friend
Morgan Stanley analyst Jeffrey Hung reiterated an Overweight rating and $95.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
